American Century Companies Inc. Has $5.47 Million Stock Position in Hims & Hers Health, Inc. $HIMS

Key Points

• American Century Companies Inc. increased its stake in Hims & Hers Health by 31.5% in the 1st quarter, owning 185,065 shares worth approximately $5.47 million.
• Several institutional investors have also significantly increased their holdings in Hims & Hers Health, with Farallon Capital Management boosting its stake by 64,338.5% during the last quarter.
• Despite a year-over-year revenue growth of 72.6%, Hims & Hers Health reported an earnings miss for the last quarter, with earnings per share of $0.17 compared to the estimated $0.18.

American Century Companies Inc. lifted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 31.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 185,065 shares of the company's stock after purchasing an additional 44,307 shares during the period. American Century Companies Inc. owned 0.08% of Hims & Hers Health worth $5,469,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Farallon Capital Management LLC grew its stake in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Nuveen LLC acquired a new position in Hims & Hers Health in the 1st quarter valued at about $58,403,000. Yong Rong HK Asset Management Ltd grew its stake in Hims & Hers Health by 41.2% in the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock valued at $70,920,000 after buying an additional 700,100 shares during the last quarter. CloudAlpha Capital Management Limited Hong Kong acquired a new position in Hims & Hers Health in the 1st quarter valued at about $20,580,000. Finally, Two Sigma Investments LP grew its stake in Hims & Hers Health by 37.9% in the 4th quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company's stock valued at $47,571,000 after buying an additional 540,274 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded down $1.76 on Friday, reaching $42.36. 16,080,388 shares of the stock were exchanged, compared to its average volume of 29,952,310. The firm's 50 day moving average is $49.98 and its 200-day moving average is $45.82. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The firm has a market cap of $9.57 billion, a PE ratio of 52.95, a P/E/G ratio of 2.98 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health's revenue for the quarter was up 72.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 60,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the transaction, the insider owned 169,940 shares of the company's stock, valued at $9,105,385.20. This represents a 26.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Oluyemi Okupe sold 23,107 shares of the stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares of the company's stock, valued at approximately $2,987,239.50. The trade was a 26.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,395,428 shares of company stock worth $71,753,898 in the last 90 days. 13.71% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Morgan Stanley restated an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a research report on Monday, June 23rd. Piper Sandler restated a "neutral" rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Reduce" and a consensus price target of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.